¤@¡³¤T¦~«×¤º¬ì±M¬ìÂå®v¦Ò¸Õµ§¸ÕÃD -- ¦Ò¥jÃD

(A) 1. ¤U¦C¦³Ãö¤ß¤º½¤ª¢(Infective Endocarditis)ªº»¡ªk¡A¦óªÌ¬O¿ù»~ªº¡H
A.¥ý¶i°ê®aªº¤ß¤º½¤ª¢ªñ¦~¼W¦h¡A¦]«Dªk¨Ï¥Î¸TÃÄ¡B¦h¥Î¤ß¤º¾¹±ñ(intracardiac device)¡B¼W¥[°h¤Æ©Ê¤ß佤¯f¤H¡B¤ÎÂåÅ@¬ÛÃöªº·P¬V¯f¤]¼W¦h
B.Âإͪ«(vegetation)¶°¦å¤pªO¡BÅÖºû¯À¡B¯fµß¤Î¤Ö¼Æªºµoª¢²Ó­M¡A¦h¨£©ó§CÀ£µÄ«Çªº¤ßŦµ²ºc
C.¤fµÄ¡B­G¸z®§¦×©Î¾Í«Ç(diverticuli)±`¬OÃì²yµß®èªº¨Ó·½¡A¦Ó¤j¸z²yµß(enterococci)±`¨Ó¦Ûªc§¿¹D
D.ªÀ°Ï·P¬V¤ß¤º½¤ª¢¦h¦]¯óºñ¦âÃì²yµß(viridans streptococci)¡Bstaphylococci¤ÎHACEK¯fµß¦Ó°_
E.­¹¹D¶W­µªi¤ß¹ÏÀˬd¥i´£°ª¤ß¤º½¤ª¢ªº¶EÂ_
 
(B) 2. ¤U¦CÃö©óMDR-TBªº±Ô­z­þ¤@­Ó¤£¥¿½T¡H
A.MDR-TB«ü¦Ü¤Ö¹ïisoniazid¤Îrifampicin¨ã§ÜÃĩʪº±wªÌ
B.MDR-TBªº¯f±w¥H¤@¶}©l§Y·P¬V¨ã§ÜÃĩʪºµß®è¬°³Ì±`¨£ªº­ì¦]
C.¦Ü¤Ö»Ý¨Ï¥Î4ºØ¦³®ÄªºÃĪ«ªvÀø18­Ó¤ë¥H¤W¡A¥B»Ý·|¶E¨ãªvÀø¦h­«§ÜÃĵ²®Ö¦³¸gÅ窺Âå®v
D.¯f±w¤£³W«hªAÃÄ¡BªAÃÄ´Á¶¡¤£¨¬§Y¦Û¦æ°±ÃĬO³y¦¨MDR-TBªº­ì¦]¤§¤@
E.¹ï©óMDR-TB¯f¤H¤§¿Ë±K±µÄ²ªÌ¡Aisoniazid¤£¾A¥Î©óªvÀø¼ç¥ñ´Áµ²®Öµß·P¬V(latent tuberculosis)
 
(A) 3. ¤U¦CÃö©ódiarrhea¤§±Ô­z¡A¦óªÌ¥¿½T¡H
A.Àˬd¤j«K¤¤ªºfat¤D¬O¿zÀËmalabsorption³Ì¨Î¤è¦¡
B.Malabsorption±wªÌ¤@©w·|¦³diarrhea
C.Non-inflammatory chronic watery diarrhea¤¤¡Asecretory diarrhea©ófasting«á·|°±¤î
D.Irritable bowel syndrome±wªÌ¤§diarrhea©ófasting«á·|«ùÄò
E.¹ïsevere diarrhea±wªÌ¡AÀ³¾¨§Öµ¹¤©opiatesÃĪ«ªvÀø
 
(B) 4. ¦³¤@¦ì65·³¨k©Ê, ÃhºÃµÇµ²¥Û, ±µ¨üIVU ( intravenous urography) Àˬd, ²Ä¤T¤Ñµo²{BUN¥Ñ33 mg/dL¤É¦Ü60 mg/dL, ¦å¤¤creatinine¥Ñ2.1 mg/dL¤É¦Ü4.6 mg/dL,¤U¦C´y­z¦óªÌ¥¿½T¡H
A.Åã¼v¾¯¤D¥Ñ¦åºÞÂX±i¤§¾÷Âà¾É­PµÇ·l¶Ë.
B.¤ßŦ°IºÜ¡]congestive heart failure¡^¯f¤H¸û®e©öµo¥Í¦¹¨Öµo¯g
C.Åã¼v¾¯¤§¾¯¶q»PµÇ·l¶Ë¤§µ{«×³q±`µLÃö.
D.Åã¼v¾¯¥i¸g¹Lreactive oxygen species¤§¾÷Âà, ¥D­n¶Ë®`µÇ¤p²y¡]glomerular cells).
E.³q±`¬°¤£¥i°f©Ê, ¤j¬ù2 ¬P´Á«á¶i®i¦Ü»Ý³zªRªvÀø
 
(D) 5. ¤U¦C¦³Ãö¥Ö½§³n²Õ´·P¬Vªº±Ô­z¦óªÌ¬°«D¡H
A.¦b¥xÆW¡A­P¯fµßKlebsiella pneumoniaeªº¤ñ¨Ò¤ñ¼Ú¬ü°ê®a°ª¥X³\¦h
B.Ãa¦º©Êµ¬½¤ª¢¬OªuµÛfascia§Ö³t½¯©µªº¤@ºØ¥Ö½§¤Î¥Ö¤U²Õ´·P¬V¡A¦º¤`²v¥i¹F26%
C. Ãa¦º©Êµ¬½¤ª¢ªºªvÀø»Ý­n¾¨¦­ªº¤â³N²M³Ð¤Î¦³®Äªº§Ü¥Í¯ÀªvÀø
D.µo¥Í¦bªÏÅ骺Ãa¦º©Êµ¬½¤ª¢¤SºÙ¬°Fournier's gangrene
E.Primary pyomyositis¬O«ü°©Àf¦Ù¤ºªºµoª¢¤ÏÀ³¨Ã¥B§Î¦¨ÁwºÅ¡A³Ì±`¨£ªº­P¯fµßºØ¬O Staphylococcus aureus
 
(B) 6. 65·³¨k©Ê¦]­Â«å¡B­¹¼¤¤£®¶¡B¦h§¿¤G­Ó¤ë¡A¤µ¦­©ü°g¨Ó«æ¶E¡A6­Ó¤ë«e¯f¤H³Q¶EÂ_ªÍÀù¡A¨­ÅéÀˬd¡G¦åÀ£88/60 mmHg ¡BPR 108/min¡Bregular¡ARR20/min¡A¦¹¥~µL¯S§O²§±`¡A©â¦åÀˬdBUN 66 mg/dL¡BCr 2.9 mg/dL¡BCa 13 mg/dL¡C¸g¹L­¹ÆQ¤ô¿é²GªvÀø«á²M¿ô¡AiPTH´ú¤£¨ì¡A­nºû«ù¦å¶t¥¿±`¡A¤U¦C¨º¤@ÃĪ«³Ì¨Î
A.Calcitonin
B.Bisphosphonate
C.Diuretic
D.Prednisolone
E.EDTA
 
(B) 7. 30·³¤k©Ê¥­±`¨­Åé°·±d¡A¦]2­Ó¤ë¨Ó±`¦­¤WµLªk¥s¿ô³Q°e¨Ó«æ¶E¡A¨­ÅéÀˬd°£¦åÀ£90/60 mmHg¡B PR 120/min¡A regular¡B µs¦½¥~¡AµL¯S®í²§±`¡C¸g¸²µå¿}ª`®g«ì´_¥¿±`¡Aª`®g«e©â¦åÀˬd¦å¿}56 mg/dL¡B insulin level 18 £gU/mL ¡A¤U¦C¨º¤@±¹¬I¦b¶EÂ_¤W³Ì«ê·í¡H
A.¸¡³¡¹q¸£Â_¼h
B.¦í°|°µ72¤p®ÉªÅ¸¡¸ÕÅç
C.®a¤¤¸²µå¿}ºÊ´ú
D.¥þ¨­¥¿¤l±½´y
E.¯ØŦ¤ºµøÃè¶W­µªiÀˬd
 
(C) 8. ¤â³¡Ãö¸`«I¥Çªº¦ì¸m¹ï¤@¨Ç­·Àã¯f¤§Å²§O¶EÂ_¨ã¦³¤£¿ùªº»ù­È.Ä´¦p¤j©æ«üªºCarpometacarpal joint (1st CMC)¤§«I¥Ç³Ì¥i¯àªº­·Àã¯f¬°¦ó?
A.Psoriatic arthritis
B.Rheumatoid arthritis
C.Osteoarthritis
D.Pseudogout
E.Gonococcal arthritis
 
(A) 9. 23·³¨k©Ê±wªÌ¦­±áºÎ¿ô®É¦³¤U­I»øµw¤Îµy·L¯kµh¡C¥t¥~¡AªÓÃö¸`¤ÎÀV³¡¥ç®É±`¦³»øµwµo¥Í¡A¸gµy·L¹B°Ê¤§«á»øµw·|½w¸Ñ¡C¦³®É¨«¸ô·|¦³¨â°¼¹«Áѳ¡¯kµh¡C½Ð°Ý¤U¦C¦óºØÀˬd¹ï¯e¯fªº¶EÂ_³Ì¦³À°§U¡H
A. Pelvis X-film (AP view)
B.Sonogram of neck and bilateral shoulder joint areas
C.HLA-B27
D.C-spine X-film (AP and lateral view)
E.Autoimmune profile
 
(C) 10. ¤U¦C®e©ö¤Þµo®ê¶ë¤§¿ò¶Ç©Ê¯Ê³´¤¤¡A¦óªÌ¦b¥xÆW³Ì±`¨£¡H
A.Antithrombin III deficiency
B.Protein C deficiency
C.Protein S deficiency
D.Factor¢ä Leiden mutation
E.Prothrombin 20210A mutation
 
(C) 11. Gefitinib (Iressa)»PErlotinib (Tarceva)¬O¤G­Ó­«­nªº«D¤p²Ó­MªÍÀù(NSCLC, non-small cell lung cancer)ªº¼Ð¹vÃĪ«¡A¹ïªF¤è¤k©Ê¡A«D§lµÒ¤§¸¢Àù(adenocarcinoma)±wªÌ¡A¤×¨ä¦³®Ä¡C¥HÃĪ«°ò¦]¾ÇªºÆ[ÂI¡A¦¹¤@¤W¥Ö¥Íªø¦]¤l±µ¨üÅé(EGFR, epidermal growth factor receptor)¹TÓi»ÄÁC»Ä¤Æ¿EúC(TK, tyrosine kinase)ªº¤p¤À¤l§í¨î¾¯¡A·í¡uEGFR°ò¦]¡v²£¥Í¦óºØÅܲ§®É¡A«Ü¥i¯à·|ªí²{¹ïGefitinib©ÎErlotinibÃĪ«¤§"§ÜÃÄ©Ê" (resistance)¡H
A.L858R (²Ä858Ói°ò»Ä¦ìÂI¤§Lysine ³QArginine¨ú¥N)
B.L747-S752 ¤§¤@¬qÓi°ò»Ä¤§°ò¦]³Q§R°£(deletion)
C.T790M (²Ä790Ói°ò»Ä¦ìÂI¤§Threonine³QMethionine¨ú¥N)
D.E746-A750¤§¤@¬qÓi°ò»Ä¤§°ò¦]³Q§R°£(deletion)
E.¥H¤WEGFR¤§°ò¦]Åܲ§¡A§¡¹ïGefitinib©ÎErlotinib¨ã°ª±Ó·P©Ê¡A¨ÃµL§ÜÃÄ©Ê
 
(B) 12. 42·³¤k©Ê¡A¬ðµo¥ªÀV³¡¯kµh¡A¥ªÁy»P¥k°¼ªÏÅé³Â¤ì¡A¥ª°¼ªÏÅ饢½Õ¡]dysmetria¡^»Pºc­µ§xÃø¡]dysarthria¡^¡A«h³Ì¦³¥i¯à¨º¤@±ø°Ê¯ßªý¶ë¡H
A.°ò©³°Ê¯ß¡]basilar artery¡^
B.´Õ°Ê¯ß¡]vertebral artery¡^
C.«e¤U¤p¸£°Ê¯ß¡]anterior inferior cerebellar artery¡^
D.«á¤j¸£°Ê¯ß¡]posterior cerebral artery¡^
E.«e¯á°Ê¯ß¡]anterior spinal artery¡^
 


< ¤@¡³¤T¦~«×¸ÕÃD¥Ø¿ý >